scholarly journals Modified Blalock-Taussig shunt following long-term administration of prostaglandin E1 for ductus-dependent neonates with cyanotic congenital heart disease

1985 ◽  
Vol 90 (3) ◽  
pp. 399-403 ◽  
Author(s):  
Michio Yokota ◽  
Ryusuke Muraoka ◽  
Minoru Aoshima ◽  
Shinichi Nomoto ◽  
Yoshishada Shiraishi ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Prostaglandin E1 ◽  
Cyanotic Congenital Heart Disease ◽  
Term Administration ◽  
Blalock Taussig Shunt

Prolonged Prostaglandin E1 Infusion in an Infant With Cyanotic Congenital Heart Disease

PEDIATRICS ◽  
1978 ◽  
Vol 61 (4) ◽  
pp. 534-536
Author(s):  
Alan B. Lewis ◽  
Paul R. Lurie
Keyword(s):  
Congenital Heart Disease ◽  
Blood Flow ◽  
Heart Disease ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Pulmonary Blood Flow ◽  
Congenital Heart ◽  
Prostaglandin E1 ◽  
Ductus Arteriosus ◽  
Cyanotic Congenital Heart Disease

A small-for-gestational-age premature infant with severe tetralogy of Fallot was treated with prostaglandin E1 to dialate the ductus arteriosus and increase pulmonary blood flow. The infusion was continued for 29 days without complication at which time surgery was performed.

The Use of Prostaglandin E1 and Blalock-Taussig Shunts in Neonates with Cyanotic Congenital Heart Disease

1979 ◽  
Vol 27 (6) ◽  
pp. 508-513 ◽  
Author(s):  
D.A. Browdie ◽  
William Norberg ◽  
Robert Agnew ◽  
Bernard Altenburg ◽  
Richard Ignacio ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Congenital Heart ◽  
Prostaglandin E1 ◽  
Cyanotic Congenital Heart Disease

scholarly journals Sickle Cell Disease with Cyanotic Congenital Heart Disease: Long-Term Outcomes in 5 Children

2016 ◽  
Vol 43 (6) ◽  
pp. 509-513 ◽  
Author(s):  
Glen J. Iannucci ◽  
Olufolake A. Adisa ◽  
Matthew E. Oster ◽  
Michael McConnell ◽  
William T. Mahle
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Congenital Heart ◽  
Cyanotic Congenital Heart Disease ◽  
Cell Disease ◽  
Long Term Outcome ◽  
Cerebrovascular Accidents

Sickle cell disease is a risk factor for cerebrovascular accidents in the pediatric population. This risk is compounded by hypoxemia. Cyanotic congenital heart disease can expose patients to prolonged hypoxemia. To our knowledge, the long-term outcome of patients who have combined sickle cell and cyanotic congenital heart disease has not been reported. We retrospectively reviewed patient records at our institution and identified 5 patients (3 girls and 2 boys) who had both conditions. Their outcomes were uniformly poor: 4 died (age range, 12 mo–17 yr); 3 had documented cerebrovascular accidents; and 3 developed ventricular dysfunction. The surviving patient had developmental delays. On the basis of this series, we suggest mitigating hypoxemia, and thus the risk of stroke, in patients who have sickle cell disease and cyanotic congenital heart disease. Potential therapies include chronic blood transfusions, hydroxyurea, earlier surgical correction to reduce the duration of hypoxemia, and heart or bone marrow transplantation.

scholarly journals Long-Term Administration of Beraprost Sodium for Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

2009 ◽  
Vol 48 (17) ◽  
pp. 1531-1534 ◽  
Author(s):  
Jun Oyamada ◽  
Manatomo Toyono ◽  
Shunsuke Shimada ◽  
Mieko Aoki-Okazaki ◽  
Masamichi Tamura ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Beraprost Sodium ◽  
Term Administration ◽  
Pulmonary Arterial
Sign in / Sign up

Export Citation Format

Share Document